This book reviews important topics in osteoporosis, with the emphasis on both clinical management and basic research of the disease. From the clinical perspective, topics covering pathogenesis, diagnosis, and treatment of osteoporosis are extensively elaborated. Several more chapters complement clinical overview of osteoporosis, that discuss the effects of nutrition and exercise to bone health, the application of biochemical markers in osteoporosis diagnosis, novel potential drug targets for osteoporosis treatment, and osteoporosis in males and in children. As the prevalence of osteoporosis now reaches epidemiological levels, epidemiology and social impacts of osteoporosis is also reviewed in the book. Basic research on osteoporosis is also highlighted in the book, with a number of chapters dedicated to the review of genetics of osteoporosis, animal models for osteoporosis, and statistical methods in osteoporosis study.

This book covers a wide spectrum of areas related to basic bone research. While bone remodeling, bone development, and osteoclast biology constitute the main contents, topics important to the understanding of bone metabolism and treatment of bone-related diseases are also intensively reviewed. Three chapters are dedicated to the classic topic of bone mechanics, which include a brief overview of the mechanostat hypothesis, a more detailed review on mechanotransduction and bone adaptation, and a chapter illustrating the basic principles of bone mechanical testing. New emerging fields such as skeletal stem cells, bone tissue engineering, phytoestrogens applications, and bone genetics study using mouse models, are also covered in detail. The book closes with a special chapter dedicated to state-of-the-art advances in bone biology research.

Since the publication of the first edition, the U.S. Surgeon General released the first-ever report on bone health and osteoporosis in October 2004. This report focuses even more attention on the devastating impact osteoporosis has on millions of lives. According to the National Osteoporosis Foundation, 2 million American men have osteoporosis, and another 12 million are at risk for this disease. Yet despite the large number of men affected, the lack of awareness by doctors and their patients puts men at a higher risk that the condition may go undiagnosed and untreated. It is estimated that one-fifth to one-third of all hip fractures occur in men. This second edition brings on board John Bilezikian and Dirk Vanderschueren as editors with Eric Orwoll. The table of contents is more than doubling with 58 planned chapters. The format is larger – 8.5 x 11. This edition of Osteoporosis in Men brings together even more eminent investigators and clinicians to interpret developments in this growing field, and describe state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy. - Brings together more eminent investigators and clinicians to interpret developments in this growing field - Describes state-of-the-art research as well as practical approaches to diagnosis, prevention and therapy - There is no book on the market that covers osteoporosis in men as comprehensively as this book

This first-ever Surgeon General's Report on bone health and osteoporosis illustrates the large burden that bone disease places on our Nation and its citizens. Like other chronic diseases that disproportionately affect the elderly, the prevalence of bone disease and fractures is projected to increase markedly as the population ages. If these predictions come true, bone disease and fractures will have a tremendous negative impact on the future well-being of Americans. But as this report makes clear, they need not come true: by working together we can change the picture of aging in America. Osteoporosis, fractures, and other chronic diseases no longer should be thought of as an inevitable part of growing old. By focusing on prevention and lifestyle changes, including physical activity and nutrition, as well as early diagnosis and appropriate treatment, Americans can avoid much of the damaging impact of bone disease and other chronic diseases. This Surgeon General's Report brings together for the first time the scientific evidence related to the prevention, assessment, diagnosis, and treatment of bone disease. More importantly, it provides a framework for moving forward. The report will be another effective tool in educating Americans about how they can promote bone health throughout their lives. This first-ever Surgeon General's Report on bone health and osteoporosis provides much needed information on bone health, an often overlooked aspect of physical health. This report follows in the tradition of previous Surgeon Generals' reports by identifying the relevant scientific data, rigorously evaluating and summarizing the evidence, and determining conclusions.

"The first-ever weight-loss plan specifically designed to stop-and reverse-age-related weight gain and muscle loss, while shrinking your belly, extending your life, and creating your healthiest self at mid-life and beyond"--

This book provides a review of the most recent data on osteoporosis and bone health, presenting a vision of diagnosis and management for the year 2021 and beyond. It covers all pertinent aspects of bone health including diagnosis, fracture prevention, optimized practice, impaired orthostasis, and falls. The book examines recent developments in therapeutics, including goal-directed therapy, individualizing therapy, sequential and combined therapies, pharmaceuticals, and anabolic vs. antiresorptive therapy. In addition, it provides an in-depth overview of osteoporosis and bone health in complex patients, covering Duchene dystrophy, renal failure, periodontal diseases, and steroid-induced osteoporosis as well as considerations for pediatric populations and men. New Horizons in Osteoporosis Management is an essential resource for physicians and related professionals, residents, fellows, graduate students and nurses in rheumatology, endocrinology, radiology, pediatrics, primary care, and internal medicine.

Completely revised and updated, and utilizing the most current evidence and practice guidelines for the treatment of osteoporosis, this comprehensive third edition discusses the basic aspects of bone metabolism, the pathophysiology of osteoporosis, current diagnostic techniques and medical treatment strategies. Osteoporosis is a common disorder that is prevalent in over 20 million Americans over the age of 60. One and a half million osteoporotic fractures occur in the United States every year, including 300,000 hip fractures. Mortality rates after hip fracture approach 25%, with another 50% of patients experiencing a major decrease in their prior level of independence and quality of life. Despite the wide prevalence and severe consequences of osteoporosis, it remains a disorder that is severely under-diagnosed and treated. In this context, specialists and primary care physicians alike are having increasing difficulty keeping up with the rapid changes to the field and incorporating these advances to clinical care. In the years since the last edition of this book was published, the osteoporosis field has changed drastically. In addition to revising and updating existing chapters and removing a few that are no longer as relevant, new chapters discuss an advanced understanding of the cellular and molecular mechanisms underlying the disorder, the introduction of new diagnostic imaging techniques, a more nuanced appreciation of the risks and benefits of osteoporosis therapies, and the introduction of two new classes of osteoporosis medications. Following the format of the second edition, and including helpful key points at the opening of each chapter, this text will present a comprehensive overview of both the basic and clinical concepts relating to each topic, when appropriate. Chapter authors were chosen based on their high level of expertise and leadership in the field. Taken together, this text should thus be of great interest to physicians of multiple specialties, allied health professionals, as well as basic and clinical researchers.